Prospective biomarker analysis in HR+/HER2- advanced or metastatic breast cancer patients treated with sacituzumab govitecan
Mafalda Oliveira, MD, PhD (Hospital Vall d'Hebron, Barcelona, Spain)
Eva Ciruelos, MD (Hospital 12 de Octubre, Madrid)